183 related articles for article (PubMed ID: 35702826)
1. Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.
Tian HX; Chen ZH; Jie GL; Wang Z; Yan HH; Wu SP; Zhang SL; Lu DX; Zhang XC; Wu YL
Cancer Med; 2023 Jan; 12(1):396-406. PubMed ID: 35702826
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
[TBL] [Abstract][Full Text] [Related]
3. Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients.
Pan Y; Yuan C; Cheng C; Zhang Y; Ma Y; Zheng D; Zheng S; Li Y; Jin Y; Sun Y; Chen H
Int J Cancer; 2019 Jan; 144(2):290-296. PubMed ID: 30230541
[TBL] [Abstract][Full Text] [Related]
4.
Hayashi T; Desmeules P; Smith RS; Drilon A; Somwar R; Ladanyi M
Clin Cancer Res; 2018 Mar; 24(6):1436-1447. PubMed ID: 29127119
[No Abstract] [Full Text] [Related]
5. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O
Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126
[TBL] [Abstract][Full Text] [Related]
6. Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma.
Qian H; Hou C; Zhang Y; Ji S; Zhong C; Li J; Zhang Q; Huang J; Li C; ChengJi
Cancer Genet; 2023 Nov; 278-279():62-70. PubMed ID: 37672936
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.
Liu DH; Zhao ZR; Lin YB; Zhou WJ; Hou JY; Ye ZH; Long H
Ann Surg Oncol; 2019 Jun; 26(6):1934-1941. PubMed ID: 30820786
[TBL] [Abstract][Full Text] [Related]
8. EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.
Zhao Y; Pan Y; Cheng C; Zheng D; Zhang Y; Gao Z; Fu F; Li H; Zheng S; Zhuge L; Mao H; Kuang M; Tao X; Peng Y; Hu H; Xiang J; Li Y; Sun Y; Chen H
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1781-1789. PubMed ID: 32361787
[TBL] [Abstract][Full Text] [Related]
9. NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.
Tlemsani C; Pécuchet N; Gruber A; Laurendeau I; Danel C; Riquet M; Le Pimpec-Barthes F; Fabre E; Mansuet-Lupo A; Damotte D; Alifano M; Luscan A; Rousseau B; Vidaud D; Varin J; Parfait B; Bieche I; Leroy K; Laurent-Puig P; Terris B; Blons H; Vidaud M; Pasmant E
Cancer Med; 2019 Aug; 8(9):4330-4337. PubMed ID: 31199580
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations.
Bowman L; Tiu R; Smyth EN; Willard MD; Li L; Beyrer J; Han Y; Singh A
Clin Lung Cancer; 2021 Jan; 22(1):32-41.e1. PubMed ID: 33221173
[TBL] [Abstract][Full Text] [Related]
11. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
Ruiz-Cordero R; Ma J; Khanna A; Lyons G; Rinsurongkawong W; Bassett R; Guo M; Routbort MJ; Zhang J; Skoulidis F; Heymach J; Roarty EB; Tang Z; Medeiros LJ; Patel KP; Luthra R; Roy-Chowdhuri S
BMC Cancer; 2020 Jan; 20(1):83. PubMed ID: 32005111
[TBL] [Abstract][Full Text] [Related]
12. The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.
Zhou W; Liu Z; Wang Y; Zhang Y; Qian F; Lu J; Wang H; Gu P; Hu M; Chen Y; Yang Z; Zhao R; Lou Y; Han B; Zhang W
Cancer Med; 2022 Mar; 11(5):1299-1309. PubMed ID: 35023616
[TBL] [Abstract][Full Text] [Related]
13. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
[TBL] [Abstract][Full Text] [Related]
14. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ; Capelletti M; Dahlberg SE; Sholl LM; Mach S; Fontes C; Shi Y; Chalasani P; Jänne PA
Clin Cancer Res; 2016 Jul; 22(13):3148-56. PubMed ID: 26861459
[TBL] [Abstract][Full Text] [Related]
16. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
17. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
19. Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).
Li XM; Li WF; Lin JT; Yan HH; Tu HY; Chen HJ; Wang BC; Wang Z; Zhou Q; Zhang XC; Su J; Chen RL; Wu YL; Yang JJ
Clin Lung Cancer; 2021 Mar; 22(2):100-109.e3. PubMed ID: 33317922
[TBL] [Abstract][Full Text] [Related]
20. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma.
Zhu J; Wang W; Xiong Y; Xu S; Chen J; Wen M; Zhao Y; Lei J; Jiang T
Cancer Med; 2023 Mar; 12(5):5545-5557. PubMed ID: 36325966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]